<DOC>
	<DOCNO>NCT02964013</DOCNO>
	<brief_summary>This safety pharmacokinetics study MK-7684 monotherapy combination pembrolizumab ( MK-3475 ) adult metastatic solid tumor available therapy expect convey clinical benefit . Part A study dose escalation phase . Part B dose confirmation phase estimate recommend Phase 2 dose ( RPTD ) MK-7684 monotherapy combination pembrolizumab . The primary hypothesis MK-7684 administer monotherapy combination pembrolizumab safe administer RPTD .</brief_summary>
	<brief_title>Study MK-7684 Alone Combination With Pembrolizumab Advanced Solid Tumors ( MK-7684-001 )</brief_title>
	<detailed_description />
	<mesh_term>Pembrolizumab</mesh_term>
	<criteria>Has histologically cytologically confirm metastatic solid tumor available therapy expect convey clinical benefit Has measureable disease Response Evaluation Criteria In Solid Tumors ( RECIST ) Has Eastern Cooperative Oncology Group performance status 0 1 Females must pregnant Women childbearing potential male participant must agree use adequate contraception course study Has provide tumor tissue sample ( archival newly obtain core excisional biopsy tumor lesion ) Has chemotherapy , radiation , biological cancer therapy major surgery within 4 week prior first dose study treatment Has recover Common Toxicity Criteria Adverse Events Grade 1 good adverse event due cancer therapeutic administer 4 week prior first dose study treatment Is currently participate participate study investigational agent use investigational device within 4 week prior first dose study treatment Has receive previous treatment another agent target T cell immunoglobulin immunoreceptor tyrosinebased inhibitory motif ( TIGIT ) receptor Has receive previous treatment immunomodulatory agent ( e.g. , antiprogrammed cell death 1/ antiprogrammed cell death ligand 1 cytotoxic Tlymphocyteassociated protein 4 ) discontinue treatment due Grade 3 high immunerelated adverse event Is expect require form antineoplastic therapy participate trial Is chronic systemic steroid therapy excess replacement dose form immunosuppressive medication . Has history previous additional malignancy unless potentially curative treatment complete evidence malignancy 5 year Has know active central nervous system ( CNS ) metastases and/or carcinomatous meningitis Has active autoimmune disease Has active infection require systemic treatment Has interstitial lung disease Has active past history ( noninfectious ) pneumonitis require steroid Has symptomatic ascites pleural effusion Has previously hematopoetic stem cell transplant solid organ transplant Is know human immunodeficiency virus ( HIV ) positive and/or know active chronic acute Hepatitis B Hepatitis C Has know psychiatric and/or substance abuse disorder would make difficult participant cooperate requirement trial Is regular user ( include recreational use ) illicit drug time signing informed consent , recent history ( within last year ) substance abuse Has receive livevirus vaccine within 30 day prior first dose study treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>